|
|
|
51-200 employees
View all
|
|
pharmaceuticals
|
|
139 Main St,Cambridge,Massachusetts,US
|
|
CANbridge Pharmaceuticals Inc. is a China-focused biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region.CANbridge has been recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In greater China, it has an exclusive licensing agreement to commercialize Hunterase®, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnology’s NERLYNX® (neratinib), in greater China, as well as rights to other novel candidates.
|
CANbridge Pharmaceuticals Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75%
|
The widely used CANbridge Pharmaceuticals Inc. email format is {f}{last} (e.g. [email protected]) with 75% adoption across the company.
To contact CANbridge Pharmaceuticals Inc. customer service number in your country click here to find.
James Xue is the CEO of CANbridge Pharmaceuticals Inc.. To contact James Xue email at [email protected]. Or you may call +86.01084148018 or 6179010398
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.